diaDexus, Inc. Stock OTC Bulletin Board

DDXS

US25245P1066

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 42.44K 39.02K 36.73K 69.02K 4.64M 69.6K 462K 180K 2.28M 185K 181K 7.88M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.56M 4.2M 3.95M 7.42M 499M 7.48M 49.72M 19.36M 245M 19.86M 19.43M 848M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
10/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ULTRAGENYX PHARMACEUTICAL INC.	+8.29%	+17.15%	-26.60%	-44.26%	2.64B
SAREPTA THERAPEUTICS, INC.	+7.48%	+12.24%	-21.34%	-87.00%	1.79B
BIONOTE, INC.	-2.66%	+0.64%	-7.77%	+1.93%	317M
DK LIFE SCIENCE CO., LTD.	+0.69%	+8.91%	-36.88%	-	61.99M
Average	+3.45%	+8.01%	-23.15%	-43.11%	1.2B
Weighted average by Cap.	+7.17%	+13.94%	-23.53%	-57.28%

	2014	2015
Net sales	26.11M 22.53M 20.71M 19.49M 36.63M 2.46B 36.94M 245M 95.55M 1.21B 98M 95.91M 4.18B	17.88M 15.43M 14.18M 13.35M 25.09M 1.69B 25.3M 168M 65.44M 828M 67.12M 65.69M 2.87B
Net income	-8.47M -7.3M -6.72M -6.32M -11.88M -799M -11.98M -79.58M -30.98M -392M -31.78M -31.1M -1.36B	-7.17M -6.18M -5.68M -5.35M -10.05M -676M -10.14M -67.36M -26.22M -332M -26.9M -26.32M -1.15B
Net Debt	-198K -171K -157K -148K -278K -18.69M -280K -1.86M -725K -9.17M -743K -727K -31.73M	5.24M 4.52M 4.16M 3.91M 7.35M 495M 7.41M 49.26M 19.18M 243M 19.67M 19.25M 840M

diaDexus, Inc. Stock OTC Bulletin Board

Stocks

DDXS

US25245P1066

Pharmaceuticals

Valuation: diaDexus, Inc.

Latest news : diaDexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile